B+
Bull case
25%
Probability
Target price
$20.00
+22.7% vs current
SGRY
Surgery PartnersANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-21
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$16.50
+1.2% vs current
B-
Bear case
25%
Probability
Target price
$11.50
-29.4% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+46.2
Score
AI commentary
Tone is cautious-neutral after the May 5, 2026 earnings release. The primary-source evidence improved because the company reaffirmed guidance and described early operating improvement, but the print did not deliver a decisive margin inflection. Immediate market reaction appears muted to slightly negative rather than strongly validating, with the May 7, 2026 anchor price at $14.31 still well below the packet's median target. Analyst revision visibility remains limited at this T+3 checkpoint, so missing follow-through should lower confidence rather than be read as bullish confirmation.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventMid-2026 portfolio optimization and capital-allocation update could reset sentimentHigh impact
Management said portfolio optimization remains critical to aligning the company with its core short-stay surgical model, while recent activist pressure keeps focus on asset sales, leverage reduction, and capital deployment. The setup creates a mid-2026 governance and capital-allocation checkpoint, but evidence of realized value is still limited. [#8-K-2026-05-05]
2026-08-01catalystQ1 guide reaffirmation now has to convert into cleaner margin and cash-flow follow-throughHigh impact
The May 5, 2026 earnings release showed revenue up 4.5% to $810.9 million and same-facility revenue up 4.4%, but same-facility cases rose only 0.6% and adjusted EBITDA slipped to $102.3 million from $103.9 million, with adjusted EBITDA margin down to 12.6% from 13.4%. Management reaffirmed full-year 2026 revenue guidance of $3.35 billion-$3.45 billion and adjusted EBITDA of at least $530 million, so the next debate is whether pricing/mix and cost discipline can rebuild margin and free cash flow rather than just hold revenue growth. [#8-K-2026-05-05]
2026-12-31catalystOutpatient migration and higher-acuity mix remain the structural upside if execution improvesHigh impact
The longer thesis still rests on outpatient surgery migration, physician recruitment, and portfolio positioning in short-stay surgical facilities, but the Q1 print shows that structural demand still needs to translate into better margins, deleveraging, and consistent earnings quality before the stock can sustain a stronger rerating. [#10-K-2026-03-02]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology